In addition, the net outcomes from the IFN signaling may also depend on the signaling strength (lFNGR1High vs. IFNGR1Low), the specific signaling molecules involved (JAK1-STAT1 vs. JAK2-STAT3/5), and tumor types and/or stages (more advanced large tumors with highly activated JAK-STAT tend to develop worse responses). This evidence concerns the gene JAK2 and neoplasm.